Related Experiment Video

Updated: Apr 21, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

10.2K

MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines

Richard Hummel1, Corina Sie1, David I Watson1

  • 1Richard Hummel, Corina Sie, David I Watson, Tingting Wang, Alfiya Ansar, Damian J Hussey, Department of Surgery, Flinders University, Bedford Park, South Australia 5042, Australia.

World Journal of Gastroenterology
|October 31, 2014
PubMed
Abstract

Insights

MicroRNA (miRNA) signatures differ in esophageal cancer cells resistant to chemotherapy. These specific miRNA profiles may influence treatment outcomes in esophageal adenocarcinoma and squamous cell carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Esophageal cancer exhibits resistance to chemotherapy.
  • MicroRNAs (miRNAs) are implicated in cancer development and progression.
  • Understanding miRNA roles in chemoresistance is crucial for treatment optimization.

Purpose of the Study:

  • To investigate microRNA (miRNA) expression profiles in chemotherapy-resistant esophageal cancer cell lines.
  • To identify potential miRNA targets involved in chemoresistance.
  • To differentiate miRNA signatures based on cancer subtype and chemotherapeutic agent.

Main Methods:

  • Utilized an in-vitro model of acquired chemotherapy resistance in esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC) cells.
  • Compared miRNA expression profiles using microarray and quantitative real-time polymerase chain reaction (PCR).
  • Evaluated the expression of chemotherapy-relevant genes targeted by dysregulated miRNAs.

Main Results:

  • Chemotherapy-resistant sublines displayed distinct miRNA signatures.
  • Signatures varied between cisplatin- and 5-fluorouracil (5-FU)-resistant cells, and between EAC and ESCC subtypes.
  • Dysregulated miRNAs, including miR-27b-3p and miR-192-5p, were linked to the posttranscriptional control of genes like KRAS and ERBB2.

Conclusions:

  • MicroRNA expression significantly impacts chemotherapy resistance in esophageal cancer.
  • Specific miRNA signatures could serve as biomarkers for predicting treatment response.
  • Further research into miRNA-targeted therapies may overcome chemoresistance.
Keywords:
ChemotherapyEsophageal cancerMicroRNAResistanceTarget

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K